Drug Manufacturers - Specialty & Generic
Healthcare
US
New York
IR
SEC
ISIN
Market Cap.:9.7 B
M
Market Capitalization - Sizes
Here you can see how we classify a market capitalization.
XS
< 100 Mil.
S
> 100 Mil.
M
> 1 Bil.
L
> 10 Bil.
XL
> 100 Bil.
P/E:-104.93
x3.3Industry Within Country Benchmark (IWCB)
The multiplier shows you the relation between a reported metric, e.g. Earnings Per Share (EPS)
and the μ EPS value of the corporate's industry.
We exclude other countries from the average calculation in order to
take into account the specific economic and regulatory conditions in that country.
EPS:-0.87
x
5.9
Industry Within Country Benchmark (IWCB)
The multiplier shows you the relation between a reported metric, e.g. Earnings Per Share (EPS)
and the μ EPS value of the corporate's industry.
We exclude other countries from the average calculation in order to
take into account the specific economic and regulatory conditions in that country.
Earnings Call
3 months, 2 weeks from now
Dividend Waiting Time
We compute the average time difference between dividend payments
and assign an indicator that holds a general grade for that frequency.
Low
Average time between dividend payments is less than 3 months.
Neutral
Average time between dividend payments is between 3 to 6 months.
High
Average time between dividend payments is more than 6 months.
n.A.
Latest Dividends History
Each bar represents a dividend payment made within the last 12 months, with the bar's height relative to the maximum dividend paid within that timeframe.
See all Dividends.
Yield
Payout
Volume LevelVolume Deviation Rating System (VDRS)
We compare the 15-minute delayed volume to the average volume and grade the percentual deviation.
High
Deviation >= 20%
Moderate High
Deviation between 10% to 20%
Moderate
Deviation between -10% to 10%
Moderate Low
Deviation between -20% to -10%
Low
Deviation between <= -20%
μ 528,434
572,735
Moderate Low
Performance Ranks (Intraday)A system to benchmark ITCI's relative intraday performance.
Each star represents "20% have worse results", e.g. 4/5 stars symbolize that the corporate had a better result than 80% of the benchmark compotion.
United States:
838th
out of
2160
Healthcare:
224th
out of
792
Drug Manufacturers—Specialty & Generic:
40th
out of
198
Peer Group:
2nd
out of
3
About
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA …
About
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA …